A panel of experts is likely to hold a meeting to decide on approving the emergency use of Covishield vaccine in India which has been developed by Serum Institue of India (SII) in collaboration with British pharmaceutical manufacturer and the Oxford University.
The Central Drugs Standard Control Organisation's Subject Expert Committee (SEC) will be taking the final call on the emergency authorisation of Covishield.
The coronavirus vaccine developed by SII and Oxford-AstraZeneca was approved for use and mass rollout in the UK on Wednesday.
